Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629409 | 0.86 | PGR (0.60) | PKMALDH1A1GAAMAPK1LMNA | |
| SCHEMBL13629552 | 0.85 | PKM (0.74) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL13629403 | 0.83 | CES1 (0.58) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL5622505 | 0.83 | CYP19A1 (0.64) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL13853023 | 0.82 | SMN1; SMN2 (0.66) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL13629417 | 0.81 | KMT2A (0.52) | MAPTMEN1KMT2AMAPK1LMNA | |
| SCHEMBL13615156 | 0.80 | FFAR4 (0.60) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL790294 | 0.79 | GAA (0.86) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL6928661 | 0.79 | UCHL1 (0.71) | CYP19A1PKMALDH1A1MAPTMEN1 | |
| SCHEMBL8752431 | 0.79 | UCHL1 (0.71) | CYP19A1PKMALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | CYP19A1 3220/4885PKM 446/4885ALDH1A1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.